Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7887028 | 0.85 | MRGPRX4 (0.49) | MRGPRX4LMNAMAPK1HTTRAB9A | |
| SCHEMBL3684044 | 0.84 | MRGPRX4 (0.51) | MRGPRX4LMNAMAPK1HTTRAB9A | |
| SCHEMBL7513592 | 0.84 | EPHX2 (0.51) | MRGPRX4LMNAMAPK1HTTRAB9A | |
| SCHEMBL29759273 | 0.84 | MRGPRX4 (0.51) | MRGPRX4LMNAMAPK1HTTRAB9A | |
| SCHEMBL3506824 | 0.82 | MAOB (0.49) | MRGPRX4MAPK1PKMTSHRCES2 | |
| SCHEMBL4259943 | 0.82 | MRGPRX4 (0.50) | MRGPRX4LMNAMAPK1HTTRAB9A | |
| SCHEMBL1237689 | 0.81 | ACE2 (0.53) | MAPK1ACE2PKMTSHRTP53 | |
| SCHEMBL29654186 | 0.81 | ACE2 (0.53) | MAPK1ACE2PKMTSHRTP53 | |
| Hydrochloric Acid SCHEMBL28099330 | 0.81 | MRGPRX4 (0.49) | MRGPRX4LMNAMAPK1HTTRAB9A | |
| SCHEMBL7882557 | 0.79 | MRGPRX4 (0.48) | MRGPRX4LMNAMAPK1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844044-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200102288-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2020-04-02 | — | — | US | disclosed |
| US-9617212-B2 | Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors | CONTROLLED CHEMICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150175540-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | CONTROLLED CHEMICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| EP-1646608-B1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO LTD (KR) | 2011-03-02 | — | — | EP | disclosed |
| EP-1646608-B1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO LTD (KR) | 2011-03-02 | — | — | EP | disclosed |
| CN-100393698-C | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparation and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO LTD (KR) | 2008-06-11 | — | — | CN | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| EP-1646608-A4 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO LTD (KR) | 2006-11-22 | — | — | EP | disclosed |
| CN-1826316-A | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparation and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO LTD (KR) | 2006-08-30 | — | — | CN | disclosed |
| EP-1646608-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL Pharmaceutical Co., Ltd. (KR) | 2006-04-19 | — | — | EP | disclosed |
| WO-2004113281-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102288-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | MRGPRX4 2347/4885LMNA 2317/4885MAPK1 2694/4885 |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | VEGFA, TUBB3, TUBA3C | MRGPRX4 3953/4885LMNA 3823/4885MAPK1 3212/4885 |
| US-10844044-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR3 | MRGPRX4 2266/4885LMNA 2328/4885MAPK1 2555/4885 |
| US-20150175540-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | MIF, MACF1, MYADM | MRGPRX4 310/4885LMNA 4349/4885MAPK1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.